Skip to Main Content

Author Details

Elahe A Mostaghel
University of Washington
1998
106
43
PMIDPaper TitleJournal TitlePublished Year
36564459Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer.Prostate Cancer Prostatic Dis2023
37905039ONECUT2 Activates Diverse Resistance Drivers of Androgen Receptor-Independent Heterogeneity in Prostate Cancer.bioRxiv2023
37874216Sigma1 Regulates Lipid Droplet-mediated Redox Homeostasis Required for Prostate Cancer Proliferation.Cancer Res Commun2023
37352376Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex.Cancer Res2023
36710203Neoadjuvant Therapy Prior to Prostatectomy: Is the Glass Half Full?Eur Urol2023
36710146A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder Cancer.Clin Genitourin Cancer2023
34225789Hormonal intervention for the treatment of veterans with COVID-19 requiring hospitalization (HITCH): a multicenter, phase 2 randomized controlled trial of best supportive care vs best supportive care plus degarelix: study protocol for a randomized controlled trial.Trials2021
33755225Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer.Prostate2021
34407973Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer.Clin Cancer Res2021
34128479Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth.J Clin Invest2021
34280785Statins and adrenal androgen levels in prostate cancer: A new twist.EBioMedicine2021
33998604Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth.J Clin Invest2021
31227306Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts.Eur Urol2020
31672619The role of adrenal derived androgens in castration resistant prostate cancer.J Steroid Biochem Mol Biol2020
31894239Inhibitory Interplay of SULT2B1b Sulfotransferase with AKR1C3 Aldo-keto Reductase in Prostate Cancer.Endocrinology2020
32567674Addressing the conundrum of male predominance in mantle cell lymphoma using androgen receptor blockade.Br J Haematol2020
30530817Alternative Acts: Oncogenic Splicing of Steroidogenic Enzymes in Prostate Cancer.Clin Cancer Res2019
31900912Canonical and Noncanonical Androgen Metabolism and Activity.Adv Exp Med Biol2019
30181386Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer.Clin Cancer Res2019
31503550Molecular determinants of response to high-dose androgen therapy in prostate cancer.JCI Insight2019
31376206Testosterone accumulation in prostate cancer cells is enhanced by facilitated diffusion.Prostate2019
31310591Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.J Clin Invest2019
31361600Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer.J Clin Invest2019
30427533A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer.Cancer2019
29263420Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade.Prostate Cancer Prostatic Dis2018
30242112Downregulation of <i>Dipeptidyl Peptidase 4</i> Accelerates Progression to Castration-Resistant Prostate Cancer.Cancer Res2018
2993612311-Oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): Implications for castration resistant prostate cancer.J Steroid Biochem Mol Biol2018
29921690Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations.Cancer Res2018
29795142Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer.Prostate Cancer Prostatic Dis2018
29287968DNA Repair Pathway Alterations in Metastatic Castration-resistant Prostate Cancer Responders to Radium-223.Clin Genitourin Cancer2018
27683182A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.Clin Cancer Res2017
28389510Association of Tissue Abiraterone Levels and <i>SLCO</i> Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer.Clin Cancer Res2017
28411207Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer.Cancer Discov2017
28385453Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.Eur Urol2017
28156002LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.Prostate2017
28350329Harnessing Solute Carrier Transporters for Precision Oncology.Molecules2017
28151719Neoadjuvant Enzalutamide Prior to Prostatectomy.Clin Cancer Res2017
28465296Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155.Mol Cancer Res2017
28115200Androgen receptor expression in mantle cell lymphoma: Potential novel therapeutic implications.Exp Hematol2017
29210989Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions.Cancers (Basel)2017
29017058Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling.Cancer Cell2017
28663228Testicular vs adrenal sources of hydroxy-androgens in prostate cancer.Endocr Relat Cancer2017
27645128Role of OATP transporters in steroid uptake by prostate cancer cells in vivo.Prostate Cancer Prostatic Dis2017
27993966Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts.Clin Cancer Res2017
26797685Classical and Non-Classical Roles for Pre-Receptor Control of DHT Metabolism in Prostate Cancer Progression.Horm Cancer2016
26318705UDP-glucuronosyltransferase Enzymes in Prostate Cancer Progression: Is Only Androgen Catabolism Involved?Eur Urol2016
27756888Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate.Oncotarget2016
27300548Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer.Med Oncol2016
27324988A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling.Prostate2016
26936914ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.Clin Cancer Res2016
  • 1 - 50 of 106

Recommended Authors

Edel M McCrea
Stanford University
Career Start Year 2016
Number of shared co-authors 0
Pedro Isaacsson Velho
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Career Start Year 2013
Number of shared co-authors 10
Alec Paschalis
The Institute for Cancer Research
Career Start Year 2009
Number of shared co-authors 10
Arun A Azad
Peter MacCallum Cancer Centre
Career Start Year 2007
Number of shared co-authors 15
Mitchell G Lawrence
Biomedicine Discovery Institute, Monash University
Career Start Year 2005
Number of shared co-authors 3
Channing J Paller
Johns Hopkins University School of Medicine
Career Start Year 2004
Number of shared co-authors 20
Rahul Aggarwal
University of California San Francisco
Career Start Year 2003
Number of shared co-authors 39
Adam Foye
University of California San Francisco
Career Start Year 2003
Number of shared co-authors 22
Ashley E Ross
Northwestern University
Career Start Year 2003
Number of shared co-authors 42
Adam Sharp
The Institute for Cancer Research
Career Start Year 2003
Number of shared co-authors 39
Antonio Hurtado-Coll
University of British Columbia
Career Start Year 2002
Number of shared co-authors 20
Luke A Selth
Adelaide Medical School, University of Adelaide
Career Start Year 2002
Number of shared co-authors 15
Mark C Markowski
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Career Start Year 2001
Number of shared co-authors 11
Jiaoti Huang
Duke University School of Medicine
Career Start Year 2000
Number of shared co-authors 34
Yuzhuo Wang
University of British Columbia
Career Start Year 2000
Number of shared co-authors 36
Eleni Efstathiou
Houston Methodist Cancer Center
Career Start Year 2000
Number of shared co-authors 29
Amina Zoubeidi
University of British Columbia
Career Start Year 2000
Number of shared co-authors 34
Renea A Taylor
Peter MacCallum Cancer Centre
Career Start Year 1999
Number of shared co-authors 5
Hayley C Whitaker
University College London
Career Start Year 1999
Number of shared co-authors 5
Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
Career Start Year 1999
Number of shared co-authors 51
Michael A Carducci
Johns Hopkins School of Medicine
Career Start Year 1995
Number of shared co-authors 34
Ganesh V Raj
University of Texas Southwestern Medical Center at Dallas
Career Start Year 1994
Number of shared co-authors 35
Fred Saad
University of Montreal Health Center
Career Start Year 1990
Number of shared co-authors 37
Guido Jenster
Erasmus University Medical Center
Career Start Year 1990
Number of shared co-authors 14
Christopher P Evans
University of California Davis
Career Start Year 1988
Number of shared co-authors 40
Nora M Navone
MD Anderson Cancer Center
Career Start Year 1987
Number of shared co-authors 24
Anders Bjartell
Skane University Hospital, Lund University
Career Start Year 1987
Number of shared co-authors 38
Eric J Small
University of California san francisco
Career Start Year 1985
Number of shared co-authors 50
Oliver Sartor
Tulane University School of Medicine
Career Start Year 1983
Number of shared co-authors 54
Mario A Eisenberger
Johns Hopkins University
Career Start Year 1977
Number of shared co-authors 35

Collaborators

Peter S Nelson
Fred Hutchinson Cancer Center
Co-authored papers 61
Bruce Montgomery
Fred Hutchinson Cancer Center, University of Washington
Co-authored papers 41
Steven P Balk
Beth Israel Deaconess Medical Center and Harvard Medical School
Co-authored papers 20
Lawrence D True
University of Washington School of Medicine
Co-authored papers 19
Stephen R Plymate
University of Washington
Co-authored papers 18
Ilsa Coleman
Fred Hutchinson Cancer Center
Co-authored papers 18
Alvin M Matsumoto
Co-authored papers 17
Mary-Ellen Taplin
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Co-authored papers 17
Daniel W Lin
Co-authored papers 16
Eva Corey
University of Washington School of Medicine
Co-authored papers 15
Evan Y Yu
University of Washington and Fred Hutchinson Cancer Research Center
Co-authored papers 12
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Co-authored papers 12
Robert L Vessella
University of Washington
Co-authored papers 12
Heather H Cheng
Fred Hutchinson Cancer Center, University of Washington
Co-authored papers 10
Colm Morrissey
Co-authored papers 8
Jonathan L Wright
University of Washington Medical Center
Co-authored papers 7
Rosina T Lis
National Cancer Institute
Co-authored papers 6
Celestia S Higano
University of Washington and Fred Hutchinson Cancer Research Center
Co-authored papers 6
Colin C Pritchard
University of Washington, USA Brotman Baty Institute for Precision Medicine
Co-authored papers 6
Alexandra Corella
Fred Hutchinson Cancer Research Center
Co-authored papers 5
Massimo Loda
Weill Medical College of Cornell University
Co-authored papers 5
Changmeng Cai
Center for Personalized Cancer Therapy, University of Massachusetts Boston
Co-authored papers 4
Huihui Ye
College of Optical Science and Engineering, Zhejiang University
Co-authored papers 4
Michael C Haffner
Fred Hutchinson Cancer Center
Co-authored papers 4
Michael R Freeman
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 3
Juan Miguel Mosquera
Caryl and Israel Englander Institute for Precision Medicine
Co-authored papers 3
Eliezer M Van Allen
Dana-Farber Cancer Institute
Co-authored papers 3
Mark A Rubin
University of Bern
Co-authored papers 3
Adam G Sowalsky
National Cancer Institute
Co-authored papers 3
Michael J Morris
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
Release 1.2